Showing results (161-170 of 215) with videos related to
Sort By:
Pageof 22
Haematologica|December 9, 2017
From transplant to novel cellular therapies in multiple myeloma: European Myeloma Network guidelines and future perspectivesFrancesca Gay, Monika Engelhardt, Evangelos Terpos, et al.Blood|February 27, 2026
Isatuximab, bortezomib, lenalidomide, dexamethasone for multiple myeloma: dynamics of MRD-negativity in the IMROZ studyRobert Z Orlowski, Meletios A Dimopoulos, Xavier Leleu, et al.Leukemia|May 4, 2023
Management of patients with multiple myeloma and COVID-19 in the post pandemic era: a consensus paper from the European Myeloma Network (EMN)Evangelos Terpos, Pellegrino Musto, Monika Engelhardt, et al.Seminars in Hematology|May 22, 2025
Report of Consensus Panel 1 from the 12th International Workshop on the management of patients with IgM and Waldenstrom's Macroglobulinemia related neuropathyShirley D'Sa, Jahanzaib Khwaja, Signy Chow, et al.BMC Cancer|January 16, 2021
Survival benefit of ixazomib, lenalidomide and dexamethasone (IRD) over lenalidomide and dexamethasone (Rd) in relapsed and refractory multiple myeloma patients in routine clinical practiceJiri Minarik, Tomas Pika, Jakub Radocha, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 15, 2014
International Myeloma Working Group consensus statement for the management, treatment, and supportive care of patients with myeloma not eligible for standard autologous stem-cell transplantationAntonio Palumbo, S Vincent Rajkumar, Jesus F San Miguel, et al.Haematologica|October 4, 2015
European Myeloma Network guidelines for the management of multiple myeloma-related complicationsEvangelos Terpos, Martina Kleber, Monika Engelhardt, et al.The Lancet. Oncology|November 25, 2015
Chemotherapy plus lenalidomide versus autologous transplantation, followed by lenalidomide plus prednisone versus lenalidomide maintenance, in patients with multiple myeloma: a randomised, multicentre, phase 3 trialFrancesca Gay, Stefania Oliva, Maria Teresa Petrucci, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 10, 2023
Bortezomib-Dexamethasone, Rituximab, and Cyclophosphamide as First-Line Treatment for Waldenström's Macroglobulinemia: A Prospectively Randomized Trial of the European Consortium for Waldenström's MacroglobulinemiaChristian Buske, Meletios A Dimopoulos, Alexander Grunenberg, et al.Blood|January 6, 2016
Triplet vs doublet lenalidomide-containing regimens for the treatment of elderly patients with newly diagnosed multiple myelomaValeria Magarotto, Sara Bringhen, Massimo Offidani, et al.Pageof 22